CALZADA LIMITED
ASX:CZD November 2013
AGM Presentation 2013 CALZADA LIMITED ASX:CZD November 2013 - - PowerPoint PPT Presentation
For personal use only AGM Presentation 2013 CALZADA LIMITED ASX:CZD November 2013 Disclaimer For personal use only Disclaimer This presentation has been prepared by Calzada Limited and is provided for general information purposes only. No
ASX:CZD November 2013
Disclaimer
This presentation has been prepared by Calzada Limited and is provided for general information purposes only. No party other than Calzada has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation. This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment
to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward looking statements) expressed in this presentation are subject to change without notice. Calzada and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, or contained in or derived from, or for any
This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect
jurisdiction in which, or to any person to whom, such an offer would be illegal.
Forward-looking statements
This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of Calzada. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Calzada or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.
Directors
David Franklyn Chairman Bruce Rathie Non Exec. David McQuillan Non Exec.
Calzada LTD
ASX Code CZD Share Price 7.3 cents Issued Shares 416m Market Cap. $30 million Cash on Hand* $6.2 million
Major Shareholders
Merchant Funds 16% Management 8% Monash / Frank Ng 4%
*Includes estimated R&D tax concession
successfully completed 20 patient clinical trial
successfully completed 10 patient clinical trial in deep surgical wounds repairing dermal tissue & enabling skin graft
Foam Polymers Other Polymers
Facial Augment.
NovoSorbTM
TNP Wound Dressings Dermal Replacement Pelvic Floor Repair Hernia Repair Orthopaedic implants Cardio- vascular Stents Bone Void Fillers Drug eluting coatings
Title Country Application/ Registration No. Biocompatible and biodegradable (di)isocyanate and polyols USA 8,529,880 Biocompatible and biodegradable (di)isocyanate and polyols USA 8,343,472 Biocompatible polymer compositions USA 8,445,581 Biocompatible polymer compositions China ZL 200780033287.6 High modulus polyurethane and polyurethane/urea compositions Australia 2008307139 High modulus polyurethane and polyurethane/urea compositions USA 8,357,767 High modulus polyurethane and polyurethane/urea compositions China 200880117872.9 FDM Process India 254392 FDM Process Malaysia MY-146259-A FDM Process China 200580014001.0 Chain extenders Australia 2006294414 Chain extenders China 200680039476.X Chain extenders Japan 2008-531485
Europe
authorisation in Europe for medical devices using NovoSorbTM
Europe
United States
What we have
dermal replacement matrix
based products
product
culminating in successful clinical trials
(2013)
2014
cartilage and a range of other indications
Osteoarthritis with AOD9604
sold as a food/drink additive or dietary supplement in the US. Publication of required animal trial safety data is nearing completion
sales of AOD9604 by compounding pharmacies
Growth Hormone activates both the IGF-1 (crossed out) and direct cellular
significant insulin resistance and other negative side-effects.
2nd hormone - IGF1 (made in the liver)
Fat
AOD9604
Growth hormone fragment
(only 8% of the GH molecule)
Bone
Muscle and Organ growth Bone length Protein synthesis
Burns fat, Inhibits storage IGF-1 and pro-diabetic effects removed
Cartilage & Muscle
Promotes repair IGF-1 pathway Direct cellular pathway
cartilage repair and recovery from lameness
G1 Saline control G2 HA treated G3 AOD treated G4 AOD plus HA
trials in 925 human subjects
cells
veterinary subjects
body fat and for muscle & cartilage repair
6, Schedule 5 to the Therapeutic Goods Regulations (extemporaneous compounding)
pharmacies for filling prescriptions
their patients
disorders